The research in inflammatory bowel diseases is centered on understanding the
autoimmune syndrome behind the two main forms:
- Chrohn’s disease which effects any part of the gastrointestinal tract
- Ulcerative Colitis - restricted to the colon and the rectum
The research projects develop and combine new medical and surgical treatment
regimens along with testing biomarkers for their ability to predict treatment
outcome and prognosis.
Publication on the
Seroreactivity to E. coli outer membrane protein C antibodies in
active inflammatory bowel disease; diagnostic value and correlation with
phylogroup B2 E. coli infection
Background: Several serologic tests,
including anti-outer membrane porin C antibody (Omp C), are used for screening
and as marker of disease course in inflammatory bowel diseases (IBD).
Conclusions: Omp C titer was not raised in patients with active IBD
compared with patients in remission. In addition, there was no difference in Omp
C level in patients with active Crohn's disease compared with controls. These
observations do not support the use of Omp C serology testing, either in disease
activity assessment, or in screening for active Crohn's disease.